Jubilant Biosys enters into exclusive out-licensing agreement with Checkpoint Therapeutics
Jubilant Biosys and Checkpoint Therapeutics announced an exclusive, worldwide license agreement under which Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment. May 27, 2016